Your ANA Is Elevated, But Nobody Can Explain Why. Your Genes Might.

HLA-DQ2 is a protein that sits on the surface of your immune cells and displays peptide fragments to the immune system. It’s your immune system’s recognition mechanism. It essentially decides what looks like a threat and what looks like self. When your HLA-DQ2 gene is present, your immune system’s threshold for recognizing certain antigens as threats becomes much lower.

Approximately 25 to 30 percent of people of European ancestry carry the HLA-DQ2 gene. The presence of HLA-DQ2 doesn’t guarantee disease, but it does make your immune system more likely to see certain proteins as foreign invaders and mount an antibody response against them. This is why HLA-DQ2 carriers have elevated risk for celiac disease, type 1 diabetes, and non-celiac gluten sensitivity, but also why they may show elevated ANA without a clear diagnosis.

You may have noticed that you feel worse after certain foods, or that your joint pain flares unpredictably. You might have a family history of autoimmune disease on one side of your family but not the other. If you carry HLA-DQ2, your immune system is recognizing threats that other people’s immune systems simply ignore.

CTLA4 is a checkpoint protein on the surface of T-cells. Its job is to apply the brakes when T-cells become too active. It’s the ‘off switch’ for immune activation. When CTLA4 is working properly, it prevents your T-cells from attacking your own tissues and keeps immune responses proportional to actual threats.

The CTLA4 +49A>G variant is carried by roughly 45 percent of the population. This variant reduces CTLA4’s ability to suppress T-cell activation, meaning your immune system’s brakes are less effective. People with this variant tend to have more active T-cells circulating at baseline, a lower threshold for immune activation, and a harder time turning immune responses off once they start.

You may have noticed that your immune system seems to overreact to minor infections or stressors. A small cold might trigger weeks of fatigue and joint pain. Stress or poor sleep can trigger a flare of symptoms that seem disproportionate to the trigger. If you carry the CTLA4 variant, your immune system is literally struggling to apply the brakes.

TNF, or tumor necrosis factor-alpha, is one of the most potent inflammatory signaling molecules your immune system produces. It’s released by immune cells to trigger inflammatory responses throughout your body. In appropriate amounts, TNF is protective. In excess, it drives systemic inflammation, tissue damage, and autoimmune activation.

The TNF -308G>A variant is carried by approximately 30 percent of people of European ancestry. People who carry the A allele tend to produce higher baseline levels of TNF-alpha, which means their immune system is running at a higher inflammatory set point. Even at rest, their inflammatory signaling is more active than in people without the variant.

You may experience chronic low-grade inflammation that shows up as persistent fatigue, achiness, or a general sense of unwellness. Your ANA may be elevated because TNF is constantly amplifying the signal that there’s a threat, even when there isn’t one. If you’re sensitive to foods or environmental triggers, TNF amplification can turn a minor irritant into a major immune response.

IL-6, interleukin-6, is an inflammatory cytokine that amplifies immune responses once they’ve started. It’s released by immune cells and acts on other immune cells to increase their activity. IL-6 is also one of the main drivers of neuroinflammation, which means elevated IL-6 doesn’t just cause body-wide inflammation, it crosses the blood-brain barrier and inflames your central nervous system.

Approximately 40 percent of the population carries the IL6 -174G>C variant that increases IL-6 production. People with the C allele tend to have higher baseline IL-6 levels and a stronger inflammatory amplification response, which drives both systemic inflammation and brain inflammation. This doesn’t necessarily show up on standard inflammatory markers like CRP, but it’s happening at the cellular level.

You may experience brain fog, difficulty concentrating, or mood changes alongside your elevated ANA and fatigue. You might have noticed that inflammation seems to affect your cognition as much as your body. If you carry high-producing IL6 variants, your immune system is amplifying inflammatory signals in your brain as well as your body.

PTPN22 is a phosphatase, an enzyme that removes phosphate groups from proteins to turn them off. In T-cells, PTPN22 acts as a fine-tuning mechanism that modulates how strongly a T-cell responds to antigen recognition. When PTPN22 is working properly, it prevents T-cell overactivation and helps maintain immune tolerance. When it’s variant, that fine-tuning is disrupted.

The PTPN22 R620W variant is carried by roughly 15 to 20 percent of people of European ancestry and is one of the most studied autoimmune risk variants. People who carry the R620W variant have altered T-cell signaling that makes them more likely to lose immune tolerance and generate antibodies against self antigens. This variant appears in people with celiac disease, type 1 diabetes, lupus, and rheumatoid arthritis, but it also appears in people with elevated ANA who haven’t yet developed diagnosed disease.

You may have a family history of autoimmune disease or a pattern of being ‘on the edge’ of multiple autoimmune conditions without meeting full diagnostic criteria for any of them. Your immune system’s T-cells may be recognizing self antigens but not yet in sufficient quantities to trigger clinical disease. If you carry PTPN22 variants, you’re at genuine risk for disease progression if triggers aren’t identified and removed.

IRF5 is an interferon regulatory factor, a transcription factor that controls the expression of interferon genes. Interferons are potent immune signaling molecules that activate antiviral and antibacterial responses. IRF5 sits upstream of these genes and decides when and how strongly to activate them. When IRF5 is variant, interferon signaling becomes amplified and dysregulated.

IRF5 variants are carried by roughly 20 to 30 percent of the population, and multiple different variants exist. People with certain IRF5 variants produce elevated interferon responses, which amplifies both antiviral immunity and autoimmune activation. This means your immune system overreacts to viral infections and may remain in a heightened antiviral state even after the infection has cleared.

You may have noticed that viral infections seem to trigger lasting immune dysfunction, or that you have a pattern of recurrent viral reactivation (like herpes simplex or EBV reactivation). Your fatigue and ANA elevation may have started after a viral infection that you never fully recovered from. If you carry IRF5 variants, your immune system’s interferon response is stuck in the ‘on’ position, continuously amplifying antiviral signaling even in the absence of active infection.